论文信息 - Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia.

Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia.

"Morphoproteomics" is defined as the identification by immunohistochemistry of the molecular circuitry of various proteins in a tumor by noting their state of activation (translocation and phosphorylation) and correlative expressions. This approach can uncover potential targets, amenable to therapeutic interventions, that are specific for an individual patient's tumor (ie, customized chemotherapy). This communication illustrates the successful application of such an approach in a patient with relapsed acute lymphoblastic leukemia.

[1] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[2] R. Kofler,et al. Sequence-specific transcription factors during glucocorticoid-induced apoptosis in acute lymphoblastic leukemia cells. , 1999, Wiener klinische Wochenschrift.

[3] P. Dhawan,et al. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. , 2002, Cancer research.

[4] C. Scheidereit,et al. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells , 2000, Leukemia.

[5] Yung-Hyun Choi,et al. Phosphorylation of NF-kappa B by calmodulin-dependent kinase IV activates anti-apoptotic gene expression. , 2003, Biochemical and biophysical research communications.